Product Description
Ki-67 may be considered as a valuable biomarker in breast cancer patients.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Non-Small-Cell Lung Cancer
Phase 2: Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500095524 |
ChiCTR2500095524 | N/A |
Not yet recruiting |
Cervical Cancer |
2028-12-31 |
|||
NCT07084558 |
TEODOR | N/A |
Recruiting |
Breast Cancer |
2028-06-30 |
2025-08-20 |
Primary Endpoints |
|
NCT06628570 |
STUDY00006091 | N/A |
Recruiting |
Anal Cancer|Squamous Cell Carcinoma |
2027-10-01 |
2025-09-09 |
Primary Endpoints|Treatments |
|
NCT05727228 |
I-share | N/A |
Recruiting |
Uterine Cancer|Cervical Cancer |
2027-02-01 |
2023-02-16 |
Primary Endpoints|Treatments |
|
ChiCTR2400079698 |
ChiCTR2400079698 | N/A |
Not yet recruiting |
Breast Cancer |
2026-12-31 |
2024-01-11 |
Treatments |
|
ChiCTR2500103788 |
ChiCTR2500103788 | N/A |
Recruiting |
Oncology Unspecified |
2026-07-31 |
|||
ChiCTR2100054369 |
ChiCTR2100054369 | N/A |
Recruiting |
Adenocarcinoma |
2023-12-31 |
|||
ChiCTR2100054094 |
ChiCTR2100054094 | N/A |
Recruiting |
Liver Cancer |
2023-12-01 |
|||
ChiCTR2000038578 |
ChiCTR2000038578 | N/A |
Not yet recruiting |
Breast Cancer |
2022-12-31 |
|||
ChiCTR2200055502 |
ChiCTR2200055502 | N/A |
Recruiting |
Breast Cancer |
2022-12-31 |
|||
ChiCTR2000029231 |
ChiCTR2000029231 | N/A |
Not yet recruiting |
Cervical Cancer |
2022-05-01 |
|||
NCT04283773 |
2019-09-05-001-R1 | N/A |
Completed |
Ovarian Cancer |
2021-04-01 |
2021-09-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04758455 |
IHS for Wilms tumour relapse | N/A |
Unknown status |
Wilms Tumor |
2021-03-01 |
2023-02-03 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2100048119 |
ChiCTR2100048119 | N/A |
Completed |
Glioma |
2020-12-01 |
|||
ChiCTR1900022725 |
ChiCTR1900022725 | N/A |
Completed |
Oncology Unspecified |
2019-08-31 |
|||
ChiCTR-OOC-15006925 |
ChiCTR-OOC-15006925 | N/A |
Recruiting |
Ovarian Cancer |
2017-09-01 |
|||
ACTRN12613001207707 |
Compass | N/A |
Completed |
Papilloma|Cervical Cancer |
2014-12-01 |
2025-02-11 |
Treatments |
|
ACTRN12618001284257 |
PROSPER 1 | N/A |
Recruiting |
Breast Cancer |
None |
2025-10-23 |
Treatments |
|
NCT05837455 |
NeoTAILOR | P2 |
Recruiting |
Breast Cancer |
2027-11-30 |
2024-05-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04997941 |
MORE-T | P2 |
Active, not recruiting |
Breast Cancer |
2024-12-31 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT01000740 |
1839IL/0052 SubStudy | P4 |
Completed |
Non-Small-Cell Lung Cancer |
2010-04-01 |
2025-08-27 |
Primary Endpoints|Treatments |